Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Taysha Gene Therapies, Inc. (TSHA)
Peridot Acquisition (PDAC.U)
Upcoming IPO
PaxMedica (PXMD)
Amesite Operating (AMST)
FG New America Acquisition (FGNA.U)
VIA optronics AG (VIAO)
Orphazyme A/S (ORPH)
Prelude Therapeutics Incorporated (PRLD)
Graybug Vision, Inc. (GRAY)
PMV Pharmaceuticals, Inc (PMVP)
FinTech Acquisition IV (FTIVU)
Vector Acquisition (VACQU)
Vision Marine Technologies (VMAR)
Boqii Holding Limited (BQ)
Lixiang Education Holding Co., Ltd. (LXEH)
Immunome Inc. (IMNM)
Palantir Technologies Inc. (PLTR)
Yalla Group Limited (YALA)
Chindata Group Holdings Limited (CD)
Asana, Inc. (ASAN)
Pulmonx Corporation (LUNG)
Mission Produce, Inc. (AVO)
Academy Sports and Outdoors, Inc. (ASO)
Priced IPO
Bentley Systems, Inc. (BSY)
Corsair Gaming, Inc. (CRSR)
GoodRx Holdings, Inc. (GDRX)
Laird Superfood, Inc. (LSF)
Unity Software, Inc. (U)
Vitru Limited (VTRU)
Athira Pharma, Inc. (ATHA)
COMPASS Pathways plc (CMPS)
Broadstone Net Lease Inc. (BNL)
Sumo Logic, Inc. (SUMO)
Pactiv Evergreen Inc (PTVE)
American Well Corporation (AMWL)
Dyne Therapeutics Inc (DYN)
JFrog Ltd. (FROG)
Snowflake Inc. (SNOW)
Metacrine, Inc. (MTCR)
StepStone Group Inc. (STEP)
Outset Medical Inc. (OM)
Lightspeed POS Inc. (LSPD)
GreenPower Motor (GP)
More companies

Checkmate Pharmaceuticals, Inc. (CMPI)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company focused on developing and commercializing their proprietary technology to harness the power of the immune system to combat cancer. Their product candidate, CMP-001, is a differentiated Toll-like receptor 9, or TLR9, agonist delivered as a biologic virus-like particle, or VLP, utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. In a clinical trial of CMP-001 in combination with a systemic checkpoint inhibitor, or CPI, in patients whose tumors were unresponsive or no longer responsive to a CPI, they have observed a best overall response rate of 28%, including post-progression responders. They have assembled a strong management team and infrastructure to evaluate CMP-001 across multiple tumor types in combination with other immunotherapy agents. Their goal is to establish CMP-001 as a foundational immuno-oncology therapy that engages the innate immune system to fight cancer and improve outcomes for patients with a broad range of solid tumors.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Barry Labinger Jon Lieber
Employees Founded
22 2015

Contacts

Address: 245 Main Street, 2nd Floor, Cambridge, MA 02142, US

Telephone: (617) 682-3625

Web page: http://www.checkmatepharma.com

IPO information

Expected Date 8/7/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $321.6
Revenues (MM) $0
Net Income (Loss) (MM) $-36.2

Voting

What do you think will happen with the CMPI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 5
Shares Revised (MM) 5
Expected offer amount (MM) $75
Realized offer amount(MM) $75
Underwriters
BofA Securities/ Jefferies/ BMO Capital Markets
CO-Managers
BTIG

Sector: Healthcare

Tweets about $CMPI

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats